Inventiva announces a licensing agreement with Hepalys Pharma, a new company registered in Japan and incubated by Catalys Pacific, in which the French biopharmaceutical company holds a 30% stake.

This exclusive agreement covers the development and commercialization of lanifibranor, Inventiva's proprietary drug candidate, for the treatment of NASH (non-alcoholic steatohepatitis) in Japan and South Korea.

Inventiva will receive an upfront payment of $10 million, and is eligible to receive milestone payments of up to $231 million, plus tiered royalties on net sales in these two countries.

Copyright (c) 2023 CercleFinance.com. All rights reserved.